Dacylglycerol kinase modulating compounds

By providing DGKα inhibitor compounds with specific structures, the problem of insufficient DGKα inhibitors in the prior art is solved, enhancing the therapeutic effects of cancer and immune diseases, especially in CAR T-cell therapy and T-cell activation.

CN117736207BActive Publication Date: 2026-05-12CARNA BIOSCI +1
View PDF 542 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CARNA BIOSCI
Filing Date
2020-12-18
Publication Date
2026-05-12

AI Technical Summary

Technical Problem

There is a lack of effective DGKα inhibitors in current technologies, especially in the treatment of cancer and immune diseases, which cannot fully exert the inhibitory effect of DGKα to enhance anti-tumor immune responses and control T cell activation.

Method used

A compound (Formula I) with a specific structure and its pharmaceutically acceptable salt are provided for inhibiting diacylglycerol kinase (DGKα), which selectively inhibits the activity of DGKα for the treatment of cancer and immune diseases.

Benefits of technology

By inhibiting DGKα, the compound enhances the anti-tumor effects of CAR T-cell therapy and promotes immune responses in T cells, providing a treatment option for cancer and immune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117736207B_ABST
    Figure CN117736207B_ABST
Patent Text Reader

Abstract

The present disclosure provides diacylglycerol kinase modulating compounds and pharmaceutical compositions thereof for the treatment of cancers, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Compounds having the following structures: Table 1A. Compounds Table 1B. Compounds Table 1C. Compounds Table 1D. Compounds Table 1H. Compounds Table 1I: Compounds Table 1J: Compounds Table 2G: Compounds Table 2J: Compounds Table 2K: Compounds Table 3F: Compounds Table 3H: Compounds Table 3I: Compounds Table 3J: Compounds Table 3K: Compounds Or its pharmaceutically acceptable salt.

2. Compounds having the following structures, Or its pharmaceutically acceptable salt.

3. Compounds having the following structures, Or its pharmaceutically acceptable salt.

4. Compounds having the following structures, Or its pharmaceutically acceptable salt.

5. Compounds having the following structures, Or its pharmaceutically acceptable salt.

6. Compounds having the following structures, Or its pharmaceutically acceptable salt.

7. Compounds having the following structures, Or its pharmaceutically acceptable salt.

8. Compounds having the following structures, Or its pharmaceutically acceptable salt.

9. Compounds having the following structures, Or its pharmaceutically acceptable salt.

10. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.